Pick a founder. Any founder. Mid-Series A, term sheet on the desk. Ask them what they're negotiating hardest on. The answer comes back the same almost every time: the percentage. The dilution. The valuation that drives both.

Now ask the same founder, three years later, what they wish they'd negotiated harder on. The answer is rarely the percentage. It's a board they can't move, an angel who won't sign, an investor whose LPs are causing problems with their bank, a strategic on the cap table whose silence is now killing the exit conversation.

Founders fight the fight they understand. The fight that decides the company is more often than not the other one.

In this issue, I look at the topics founders ignore in funding negotiations and regret later. Some are common. Some are edge cases you may never run into. Walking through them does one thing: it moves you out of a dilution-only frame and into the fuller picture of what each line on your cap table actually allows the people behind it to do.

Why founders keep winning the wrong cap table fight

Most founders fight hard on dilution. They fight loosely, if at all, on control. That trade compounds. By Series B, the percentage points you saved at seed are the smaller half of the story. The terms you accepted alongside them are the bigger half.

Cap table management gets discussed as if it were one thing: the arithmetic of who owns what. It's actually multiple things. A serious cap table conversation also covers capital structure, governance, and control. Most founders work hard on the percentages and treat the rest as paperwork. The cost of doing that compounds quietly, until exactly the moment you can't afford it.

The math everyone fixates on

Let's start with the numbers as, in my experience, this is the part every founder knows inside out. A small example:

- You and a co-founder begin 50/50.

- You raise a seed round at €5M post-money for €1M. Your stake drops from 50% to 40% each.

- Series A: you raise €5M at €25M post-money. You're at 32% each.

- Additionally, a 20% option pool gets carved in (as it's quite common). You're at roughly 25%.

- Series B at €60M post-money for €15M. You are at around 19%.

That's the canonical chart. It's accurate. It's also why founders walk into every term sheet with one question front of mind: how do I lose less?

That question is fine. It's just not enough on its own.

Why it's important to look beyond the numbers

Focusing on dilution is important, don't get me wrong. But it should always be paired with how you design your capital structure overall.

The pattern I keep seeing: founders price-shop term sheets and treat control as an afterthought. They save a percentage point of dilution. In exchange, they accept a board they'll manage for four years, voting rights scattered across people they can't reach, and approval rights that turn ordinary decisions into negotiations.

Then it backfires. Sometimes immediately. Sometimes three rounds later, when an exit conversation collides with an angel who can't be found, an investor who blocks a clean transaction, or a strategic on the cap table that has quietly closed every other door.

Four places where control quietly slips

None of these will hit every cap table. All of them are worth modelling against your own.

1. The option pool sleight of hand.

This shows up in nearly every Series A and most Series Bs. The lead asks for, say, a 20% post-closing option pool. Where it gets booked decides who pays for it.

- Pre-money pool: the dilution comes out of founders and existing shareholders before the new money lands. The new investor's percentage stays whole.

- Post-money pool: everyone gets diluted, including the new investor.

The math difference on a single round is a few percentage points but the compounding difference across three rounds is meaningful. Founders who win a higher headline valuation but accept pre-money pool placement have, in most cases, accepted a worse deal. The full truth also is: you can't always negotiate this away. But you can always notice it.

2. The angels you can't reach.

A discipline worth setting up at seed: voting rights pooling for small shareholders. They stay separate as owners, but they vote through a single representative. One conversation, one signature, one path through a routine consent.

How this looks in practice

I heard a story at a recent founder event. A B2B founder in heavy-machinery software has a stack of retired industrial executives on the cap table. They're enthusiastic. They're also retired. They read every update line by line. They reply with detailed questions, comments, and suggestions. Each consent round becomes a project.

The financial dilution from those angels is small. The operational dilution is real. Across most European jurisdictions, you can't just ignore them. They have rights tied to ordinary business decisions, including things as routine as approving the annual accounts. And the harder version of this problem, the one most founders never model, is a shareholder who dies, falls seriously ill, or disappears into a contested inheritance or a six-month estate process. A 5% shareholder you can't reach can deadlock ordinary business until that situation resolves.

Pool the small ones. Build the structure into your seed term sheets. Drag-along and tag-along provisions add another layer of protection. Don't try to retrofit any of this later, when you have eleven angels and one of them is on holiday and you need a signature this week.

3. One board seat per share class.

I know this one is not easy to achieve but it can make your life a lot easier: one board seat per share class, regardless of how many lead-grade investors come in. Seed gets one. Series A gets one. If a round has three institutional investors who all want representation, that's their problem to solve, not yours to absorb.

This is unpopular. Every major investor wants a seat. Most are used to getting one. The reason to push back: a four-person board today is a six-person board after Series B and an eight-person board after Series C. At some point you're not running a company, you're running a board.

4. The investor you didn't actually diligence.

Founders diligence funds on track record, fund size, portfolio fit. They rarely diligence them on the question: who are the LPs?

The downside is asymmetric. An investor with a sanctions-list LP, a politically exposed name, or a structure that triggers KYC questions can make you persona non grata at every bank you touch. For fintechs that can be existential. For everyone else it's a slow corrosion: account openings that take six months, a payment provider that quietly drops you, a buyer in due diligence who walks because their compliance team flagged your cap table.

"It's our Fund VII" isn't a sufficient answer. Push to the layer below. Most reputable funds will respond. The ones that don't are giving you the answer in a different way.

The strategic investor problem

The last one is a bit of an outlier, hence I'm giving it its own space. Strategic investors, especially at later stages, come with a specific cost most founders underweight: every strategic on your cap table can potentially close a door at one of their competitors.

If your strategic doesn't acquire you, that might be a signal to every other potential acquirer in the space. The bank, the platform, the corporate that knew you best chose not to buy. Why? Even when the answer is benign, you're now selling against a question that didn't exist before.

That doesn't mean refusing strategics, instead you should rather price them properly. If a strategic on your Series B is worth a notable improvement on terms or commercial access, fine. If it's worth nothing extra beyond the brand on the page, you might have handed away exit optionality.

Why this compounds exactly at Series A and B

The equity you give away at €2M ARR determines how much you own at €30M ARR. That holds for dilution. It holds just as strongly for governance.

The board you set up at Series A is the board you live with through Series C unless you actively rebuild it. The voting structure you accept at seed is the one that constrains your Series B exit. The strategic you welcome at Series B is the strategic whose silence speaks at exit.

The early stages are when you have the most negotiating power you'll ever have over these terms. They're also the stages where you spend that power almost entirely on price.

Most founders fight for the percentage. Few fight for the terms behind it. The first wins a round. The second wins the company.